

## Vixarelimab

Cat. No.:	HY-P99519
CAS No.:	2243320-83-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash<sup>[1]</sup>.

#### In Vitro

Vixarelimab (KPL-716) (0.0001-0.1 µg/mL) results in increased MCP-1/CCL2 levels at a concentration of 0.0001 µg/mL in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF) cells and a significant decrease in MCP-1/CCL2 levels in both cells at concentrations of 0.001 µg/mL or higher<sup>[1]</sup>.

Vixarelimab (KPL-716) (0.0001-0.1 µg/mL) pretreatment results in reduced levels of MCP-1/CCL2 in both Oncostatin M (OSM) induced as well as OSM plus IL-4 induced HEK and HDF cells and the maximum effect is observed at concentrations of 0.01 µg/mL and 0.1 µg/mL<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100(14):adv00197.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA